MannKind Corporation drives 2026 momentum via Afrezza and FUROSCIX; label updates and execution risks define pharma ...
On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results